Answers are grounded in this paper and cite their sources.
Background: Diagnosis of breast cancer is usually done by triple assessment, which includes clinical, radiological, and pathological examination. Fine-needle Aspiration Cytology (FNAC) provides significant benefits as a diagnostic test with its rapidity of diagnosis, low cost, high rate of acceptance by patients, and high accuracy. In the present study, we retrieved the breast FNAC reports from the cytopathology laboratory and applied the International Academy of Cytology (IAC) Yokohama reporting system. Materials and Methods: The study encompassed all breast FNAC samples received in the laboratory from January 2024 to December 2024. Conventional smears were prepared from palpable lumps in the breast. These slides were fixed in ethanol. Following fixation, they were stained with hematoxylin and eosin. All the cases were classified according to the IAC Yokohama reporting system and correlated with histopathology wherever possible. Results: The study included a total of 257 breast aspirates from January 2024 to December 2024. The age group of patients ranged from 17 years to 72 years, with the majority of cases belonging to the 3 rd and 4 th decades, and 12 were male. Of the total 257 cases, 11 cases (4.2%) belonged to Category I (insufficient), 168 (65.6%) to Category II (benign), 21 (8.2%) to Category III (atypical), 13 (5%) to Category IV (suspicious for malignancy), and 44 (17%) to Category V (malignancy). Conclusion: IAC Yokohama’s use of FNAC for breast diagnostics offers an efficient and minimally invasive approach for the early detection of breast abnormalities, providing healthcare professionals with valuable insights to guide treatment decisions.
No takes yet. Share an insight, caveat, or question.
Mahankali et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: